Low levels of ATM in breast cancer patients with clinical radiosensitivity

Adjuvant radiotherapy for cancer can result in severe adverse side effects for normal tissues. In this respect, individuals with anomalies of the ATM (ataxia telangiectasia) protein/gene are of particular interest as they may be at risk of both breast cancer and clinical radiosensitivity. The associ...

Full description

Saved in:
Bibliographic Details
Published in:Genome integrity 2010-06, Vol.1 (1), p.9-9
Main Authors: Fang, Zhiming, Kozlov, Sergei, McKay, Michael J, Woods, Rick, Birrell, Geoff, Sprung, Carl N, Murrell, Dédée F, Wangoo, Kiran, Teng, Linda, Kearsley, John H, Lavin, Martin F, Graham, Peter H, Clarke, Raymond A
Format: Article
Language:English
Subjects:
Breast cancer
Cancer patients
Care and treatment
Genetic aspects
Systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adjuvant radiotherapy for cancer can result in severe adverse side effects for normal tissues. In this respect, individuals with anomalies of the ATM (ataxia telangiectasia) protein/gene are of particular interest as they may be at risk of both breast cancer and clinical radiosensitivity. The association of specific ATM gene mutations with these pathologies has been well documented, however, there is uncertainty regarding pathological thresholds for the ATM protein. Semi-quantitative immuno-blotting provided a reliable and reproducible method to compare levels of the ATM protein for a rare cohort of 20 cancer patients selected on the basis of their severe adverse normal tissue reactions to radiotherapy. We found that 4/12 (33%) of the breast cancer patients with severe adverse normal tissue reactions following radiotherapy had ATM protein levels < 55% compared to the mean for non-reactor controls. ATM mutations are generally considered low risk alleles for breast cancer and clinical radiosensitivity. From results reported here we propose a tentative ATM protein threshold of ~55% for high-risk of clinical radiosensitivity for breast cancer patients.
ISSN:2041-9414
2041-9414
DOI:10.1186/2041-9414-1-9